- Home
- MIRM vs IBOC Comparison
MIRM vs IBOC Comparison
Compare MIRM & IBOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- IBOC
- Stock Information
- Founded
- MIRM 2018
- IBOC 1966
- Country
- MIRM United States
- IBOC United States
- Employees
- MIRM N/A
- IBOC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- IBOC Major Banks
- Sector
- MIRM Health Care
- IBOC Finance
- Exchange
- MIRM Nasdaq
- IBOC Nasdaq
- Market Cap
- MIRM 3.8B
- IBOC 4.2B
- IPO Year
- MIRM 2019
- IBOC N/A
- Fundamental
- Price
- MIRM $72.65
- IBOC $66.38
- Analyst Decision
- MIRM Strong Buy
- IBOC
- Analyst Count
- MIRM 11
- IBOC 0
- Target Price
- MIRM $79.00
- IBOC N/A
- AVG Volume (30 Days)
- MIRM 560.3K
- IBOC 211.4K
- Earning Date
- MIRM 11-04-2025
- IBOC 11-04-2025
- Dividend Yield
- MIRM N/A
- IBOC 2.11%
- EPS Growth
- MIRM N/A
- IBOC 1.85
- EPS
- MIRM N/A
- IBOC 6.61
- Revenue
- MIRM $429,161,000.00
- IBOC $808,643,000.00
- Revenue This Year
- MIRM $53.14
- IBOC N/A
- Revenue Next Year
- MIRM $19.83
- IBOC N/A
- P/E Ratio
- MIRM N/A
- IBOC $10.04
- Revenue Growth
- MIRM 62.33
- IBOC 1.28
- 52 Week Low
- MIRM $36.88
- IBOC $54.11
- 52 Week High
- MIRM $78.55
- IBOC $76.91
- Technical
- Relative Strength Index (RSI)
- MIRM 52.77
- IBOC 43.70
- Support Level
- MIRM $68.34
- IBOC $65.93
- Resistance Level
- MIRM $71.96
- IBOC $68.50
- Average True Range (ATR)
- MIRM 2.53
- IBOC 1.56
- MACD
- MIRM -0.13
- IBOC 0.05
- Stochastic Oscillator
- MIRM 56.54
- IBOC 43.91
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.